AXGN Company Profile and Key Details
NASDAQ : AXGN
AxoGen
$39.49
-1.09-2.69%
At Close 4:00 PM73.89
BESG ScoreESG Rating
Price Chart
Stock Price Today
AxoGen, Inc. (AXGN) stock declined over -2.69%, trading at $39.49 on NASDAQ, down from the previous close of $40.58. The stock opened at $40.62, fluctuating between $39.09 and $41.52 in the recent session.
Stock Snapshot
40.58
Prev. Close
2.1B
Market Cap
39.09
Day Low
103.92
P/E Ratio
0.38
EPS (TTM)
-0.48
Cash Flow per Share
40.62
Open
53.18M
Number of Shares
41.52
Day High
98.28%
Free Float in %
2.22
Book Value
1.11M
Volume
Relevant Articles
SEC Fillings
Current Report (8-k)
| Filing Date | Accepted Date | |
|---|---|---|
Annual Report (10-k)
| Filing Date | Accepted Date | |
|---|---|---|
Stock Price History Chart
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Jul 13, 2026 | 40.06 | 41.52 | 39.09 | 39.49 | 1.28M |
| Jul 10, 2026 | 43.42 | 43.65 | 39.55 | 40.58 | 1.95M |
| Jul 09, 2026 | 43.25 | 43.89 | 42.80 | 43.62 | 1.54M |
| Jul 08, 2026 | 43.98 | 44.08 | 42.22 | 42.75 | 1.05M |
| Jul 07, 2026 | 45.79 | 46.77 | 44.20 | 44.57 | 1.22M |
| Jul 06, 2026 | 46.45 | 46.95 | 43.90 | 45.97 | 1.63M |
| Jul 02, 2026 | 44.30 | 46.47 | 42.18 | 45.89 | 2.4M |
| Jul 01, 2026 | 46.36 | 46.95 | 43.85 | 44.02 | 1.36M |
| Jun 30, 2026 | 44.61 | 46.26 | 43.33 | 46.19 | 1.2M |
| Jun 29, 2026 | 44.51 | 45.85 | 43.76 | 44.72 | 1.09M |
| Jun 26, 2026 | 44.41 | 45.19 | 43.52 | 44.93 | 3.21M |
| Jun 25, 2026 | 42.54 | 44.57 | 42.24 | 44.49 | 1.61M |
| Jun 24, 2026 | 44.85 | 46.00 | 41.35 | 42.52 | 2.11M |
| Jun 23, 2026 | 44.06 | 45.98 | 44.01 | 44.69 | 1.09M |
| Jun 22, 2026 | 44.83 | 45.63 | 43.95 | 44.95 | 856.72K |
| Jun 18, 2026 | 45.50 | 45.83 | 43.85 | 44.84 | 1.25M |
| Jun 17, 2026 | 42.46 | 45.68 | 42.25 | 44.57 | 1.78M |
| Jun 16, 2026 | 44.00 | 44.65 | 43.13 | 43.40 | 1.98M |
| Jun 15, 2026 | 43.50 | 44.76 | 43.20 | 43.74 | 2.88M |
| Jun 12, 2026 | 42.49 | 43.54 | 41.53 | 43.00 | 1.34M |
Contact Details
About Company
AxoGen, Inc., along with its subsidiaries, specializes in creating and distributing medical devices for the surgical repair of injured or severed peripheral nerves. Their comprehensive product portfolio offers several innovative solutions. The Avance Nerve Graft is a ready-to-use, biologically active human nerve allograft designed to bridge gaps in severed nerves. This avoids the need for a second surgical site for tissue donation, thereby eliminating associated complications. For facilitating the gentle reconnection of severed peripheral nerves, the company offers the AxoGuard Nerve Connector, an extracellular matrix (ECM) derived from porcine submucosa. This same porcine submucosa ECM forms the basis of the AxoGuard Nerve Protector, which is utilized to encase and safeguard damaged peripheral nerves, supporting their reconstruction and preventing unwanted adhesions from surrounding soft tissues. Another ECM product, the AxoGuard Nerve Cap, isolates the nerve end from its environment to help mitigate the formation of painful neuromas. Furthermore, AxoGen provides the Avive Soft Tissue Membrane, a processed human umbilical cord membrane that functions as an absorbable covering for soft tissues, used to separate tissues within the surgical area. An additional tool available is the AxoTouch two-point discriminator, used for evaluating the density of nerve innervation on the skin's surface. These products are supplied to hospitals, surgery centers, and military medical facilities, catering to plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen's market reach extends across the United States, Canada, Germany, the United Kingdom, other European nations, South Korea, and internationally. The company's main operations are situated in Alachua, Florida.
Company Information
| Employees | 622 |
| Beta | 1.09 |
| Sales or Revenue | $159.01M |
| 5Y Sales Change% | 0.64% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Medical - Devices |
Stock Peers
ISRG
0.34+0.08%
Intuitive Surgical, Inc.$407.12SWAV-0.08-0.02%
ShockWave Medical, Inc.$334.75UFPT0.34+0.14%
UFP Technologies, Inc.$237.25ALGN1.14+0.64%
Align Technology, Inc.$180.59MASI00
Masimo Corporation$179.95PODD0.78+0.48%
Insulet Corp.$162.06IRTC2.55+2.20%
iRhythm Technologies, Inc.$118.68IRMD0.49+0.50%
IRadimed Corporation$97.69ESTA-0.13-0.15%
Establishment Labs Holdings Inc.$87.90LIVN0.42+0.51%
LivaNova PLC$82.98Company Overview
AxoGen, Inc. (NASDAQ:AXGN) closed at $39.49 USD, losing -$1.09 (-2.69%) from the previous close of $40.58. The stock is currently mid-range between its 52-week high and low $11.25 and $46.95. With a market capitalization of about $2.10 billion, AxoGen, Inc. is classified as a mid-cap and shows market-like volatility (beta ~1.09). Key stats such as the average daily volume over the past year has been around 1.26 million shares, in line with its 52-week average. Headquartered in Alachua, FL, AxoGen, Inc. operates in the Healthcare sector and the Medical - Devices industry. Led by CEO Michael D. Dale, the company employs approximately 622 people and listed since December 17, 1986. AxoGen, Inc., along with its subsidiaries, specializes in creating and distributing medical devices for the surgical repair of injured or severed peripheral nerves.
Technical Performance
Short-term trend indicators are bearishly aligned (SMA20 -6.38%, SMA50 -3.21%, SMA200 54.44%). The stock’s 14-day RSI is 42.93 (neutral), while the ATR of 1.88 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -11.39% below its high and over 246.17% above its low. Average 10-day trading volume of 1.45 million shares is slightly above the 3-month average of 1.24 million, indicating heightened recent market interest.
Valuation Metrics
AxoGen, Inc. trades at a P/E ratio of -62.21, slightly below the S&P 500 average, with a price-to-sales ratio of 8.78 and a price-to-book ratio of 8.29 trading at moderately above to book value. The P/FCF stands at 234.13, also above market averages.
Dividend & Fair Value
AxoGen, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$17.73. This means the shares are trading below this model’s fair value.
Earnings & Analyst Outlook
AxoGen, Inc. generated EPS of -$0.34 over the past year. Five-year average earnings growth is 10.54%. Wall Street analysts project EPS growth of 49.04% annually over the next five years. The latest quarter delivered EPS of $0.07. The next quarter is forecast at $0.07. Next year's EPS is expected at $78.07. Analyst sentiment is bullish. Analyst rating data shows there are 7 Strong Buy ratings, 11 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $50.00 to $25.00. The high target offers 26.61% upside. The low target suggests -36.69% downside. The mean target is $38.94. This offers -1.39% upside. AxoGen, Inc. earnings surprise history is a mixed track record. The quarter that ended April 28, 2026, missed forecasts by -41.67%. The prior quarter beat by -21.16%. Over the last six quarters, Apple has recorded several small beats. These include 100.0% in February 25, 2025.
Shareholding & Insider Activity
AxoGen, Inc. has 53.18 million shares outstanding. The public float is 52.04 million shares, elevated short interest at 7.98% of float. This equals 3.66 million shares. The short ratio is 3.5 days. Institutional investors hold 98.3% of the float. Insiders own 5.43%. Zaderej Karen L. holds 1.12 million shares, Gold Mark Stephen has 346.76 thousand shares and Freitag Gregory Gene has 271.59 thousand shares. Over the past six months, insider transactions show net selling. They sold 42.62 thousand shares across 7 transactions.
Financial & Profitability Overview
On valuation metrics, AxoGen trades at a P/E of -62.21, P/S of 8.78 and P/B of 8.29. The current ratio is 7.10 and quick ratio is 5.33. Operationally, the company’s inventory turnover is 1.29 and cash conversion cycle is 179.45 days. Debt-to-equity is 0.08, supported by a cash flow-to-debt ratio of 0.75.
Quarterly Financial Highlights
The company ended the quarter with $37.03M in cash and short-term investments, a total debt of $69.29M, and net debt of $32.27M. Total assets were $196.83M, with equity of $95.67M. Financials further reflected weakness, with operating cash flow of - $5.72M, free cash flow of - $20.63M, and capital expenditures of - $14.92M.
Price Forecast & Outlook
Our AI price prediction model suggests that AxoGen, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 3.6%, with price expected at $40.91 by July 27, 2026, within a range of $39.44 to $42.42 3-Month Outlook: Projected rise of 38.82%, reaching $54.82 by October 08, 2026, with a range of $54.05 to $55.58. 1-Year Outlook: Projected gain of 27.2%, with price at $50.23 by July 13, 2027, within a range of $48.42 to $52.54.
Key Takeaways
AxoGen, Inc. (NASDAQ:AXGN) shares are flat -2.63% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows AxoGen, Inc. trading at a premium to the broader market with a P/E of -62.21. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $26.29, suggesting -33.43% downside. Our AI forecast model points to short-term strength (3.6% over two weeks), a medium-term rise (38.82% over three months), and a longer-term gain (27.2% over one year), with expected trading ranges indicating moderate volatility.
Frequently Asked Questions
What is the current AxoGen, Inc. (AXGN) stock price?
AxoGen, Inc. (NASDAQ: AXGN) stock price is $39.49 in the last trading session. During the trading session, AXGN stock reached the peak price of $41.52 while $39.09 was the lowest point it dropped to. The percentage change in AXGN stock occurred in the recent session was -2.69% while the dollar amount for the price change in AXGN stock was - $1.09.
AXGN's industry and sector of operation?
The NASDAQ listed AXGN is part of Medical - Devices industry that operates in the broader Healthcare sector. AxoGen, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Who are the executives of AXGN?
Mr. Gregory Davault
Vice President of Marketing
Ms. Maria D. Martinez
Chief HR Officer
Mr. Marc A. Began
Executive Vice President
Ms. Karen Zaderej
Chairman, Pres & Chief Executive Officer
Mr. Peter J. Mariani
Executive Vice President & Chief Financial Officer
Ms. Doris Quackenbush
Vice President of Sales
Mr. Bradley L. Ottinger J.D.
Gen. Counsel & Chief Compliance Officer
Mr. Jens Schroeder Kemp
Chief Marketing Officer
Mr. Erick DeVinney
Vice President of Peripheral Nerve Science and Clinical Innovation
Ed Joyce
Director of Investor Relations
Mr. David Hansen
Vice President of Fin. & Treasurer
Mr. Michael Donovan
Vice President of Operations
Mr. Angelo G. Scopelianos Ph.D.
Chief R&D Officer
Ms. Isabelle Billet
Chief Strategy & Bus. Devel. Officer
Vice President of Marketing
Ms. Maria D. Martinez
Chief HR Officer
Mr. Marc A. Began
Executive Vice President
Ms. Karen Zaderej
Chairman, Pres & Chief Executive Officer
Mr. Peter J. Mariani
Executive Vice President & Chief Financial Officer
Ms. Doris Quackenbush
Vice President of Sales
Mr. Bradley L. Ottinger J.D.
Gen. Counsel & Chief Compliance Officer
Mr. Jens Schroeder Kemp
Chief Marketing Officer
Mr. Erick DeVinney
Vice President of Peripheral Nerve Science and Clinical Innovation
Ed Joyce
Director of Investor Relations
Mr. David Hansen
Vice President of Fin. & Treasurer
Mr. Michael Donovan
Vice President of Operations
Mr. Angelo G. Scopelianos Ph.D.
Chief R&D Officer
Ms. Isabelle Billet
Chief Strategy & Bus. Devel. Officer
How AXGN did perform over past 52-week?
AXGN's closing price is 251.02% higher than its 52-week low of $11.25 where as its distance from 52-week high of $46.95 is -15.89%.
How many employees does AXGN have?
Number of AXGN employees currently stands at 622.
Link for AXGN official website?
Official Website of AXGN is: https://www.axogeninc.com
How do I contact AXGN?
AXGN could be contacted at phone 386 462 6800 and can also be accessed through its website. AXGN operates from 13631 Progress Boulevard, Alachua, FL 32615, United States.
How many shares of AXGN are traded daily?
AXGN stock volume for the day was 1.11M shares. The average number of AXGN shares traded daily for last 3 months was 1.26M.
What is the market cap of AXGN currently?
The market value of AXGN currently stands at $2.10B with its latest stock price at $39.49 and 53.18M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.
© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep